Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05386108
What this trial is testing

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Who this might be right for
Breast NeoplasmsBrain NeoplasmsNeoplasms by Site+5 more
Stemline Therapeutics, Inc. 73
Testing effectiveness (Phase 2)Looking for participantsNCT05181033
What this trial is testing

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
National University Hospital, Singapore 120
Large-scale testing (Phase 3)Study completedNCT02297438
What this trial is testing

Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Who this might be right for
Breast Neoplasms
Pfizer 340
Testing effectiveness (Phase 2)Study completedNCT01963481
What this trial is testing

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

Who this might be right for
Metastatic Beast Cancer
NYU Langone Health 23
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Not applicableEnded earlyNCT01957514
What this trial is testing

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+2 more
University of Washington 31
Large-scale testing (Phase 3)Ended earlyNCT04869943
What this trial is testing

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Veru Inc. 52
Testing effectiveness (Phase 2)Study completedNCT03312738
What this trial is testing

Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 159
Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759248
What this trial is testing

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 55
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Early research (Phase 1)Study completedNCT03065010
What this trial is testing

Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Biocad 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07729046
What this trial is testing

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Who this might be right for
Metastatic Invasive Breast CancerResistant Breast CancerER+, HER2-, Metastatic Breast Cancer
University of California, San Diego 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05306340
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Who this might be right for
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc. 373
Not applicableLooking for participantsNCT06666439
What this trial is testing

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

Who this might be right for
Metastatic Invasive Lobular Carcinoma (mILC)
Julia Foldi 20
Early research (Phase 1)Looking for participantsNCT07318805
What this trial is testing

Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more
Pfizer 260
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Next Page